




A New Patient Pathway at [FACILITY]

The HeartFlow FFR_{CT} Analysis: A Non-Invasive Assessment of CAD



[DATE]
[TIME]
[LOCATION]

Dear Dr. [LAST NAME]:

I am pleased to share that [PRACTICE / FACILITY NAME] now offers the HeartFlow FFR_{CT} Analysis, a personalized cardiac test that will help our physicians determine the appropriate pathway for each patient with stable coronary artery disease (CAD).

Please join us [DATE REFERENCE, I.E. "NEXT TUESDAY"] to be among the first physicians at [FACILITY] to receive training on the HeartFlow Analysis.

The HeartFlow Analysis is the first available non-invasive technology that uses standard coronary CTA scans to offer physicians lesion-specific insights into both the extent of a patient's arterial blockage and the impact that the blockage has on blood flow to the heart. There has been a growing amount of support for the coronary CTA + HeartFlow FFR_{CT} pathway through both the ACC/AHA Guidelines as well as recently released data in 2022 from the PRECISE trial. It's clear that a revolutionary shift in the diagnosis and management of CAD is underway, supporting both a better patient experience¹ and lowering healthcare system costs.

I sincerely hope that you will be able to join us as we move forward in setting a new standard for cardiovascular assessment at [FACILITY]. To RSVP, please contact [NAME] at [PHONE/EMAIL].

We look forward to seeing you there.

Warmest regards,

[NAME, TITLE]

1. Douglas et al. PLATFORM Trial. Eur Heart J. 2015;36(47):3359-67.